Citigroup Inc Ardelyx, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Ardelyx, Inc. stock. As of the latest transaction made, Citigroup Inc holds 174,834 shares of ARDX stock, worth $910,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares

174,834

Previous 145,091 20.5%

Holding current value

$910,885

Previous $1.08 Million 12.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.28 - $7.57 $157,043 - $225,154	29,743 Added 20.5%	174,834 $1.2 Million
Q2 2024 Aug 12, 2024	SELL	$5.89 - $9.31 $4.7 Million - $7.43 Million	-798,402 Reduced 84.62%	145,091 $1.08 Million
Q1 2024 May 10, 2024	BUY	$6.05 - $9.74 $2.35 Million - $3.78 Million	387,917 Added 69.82%	943,493 $6.89 Million
Q4 2023 Feb 09, 2024	BUY	$3.29 - $6.64 $284,397 - $573,981	86,443 Added 18.43%	555,576 $3.44 Million
Q3 2023 Nov 09, 2023	SELL	$3.3 - $4.83 $580,958 - $850,311	-176,048 Reduced 27.29%	469,133 $1.91 Million
Q2 2023 Aug 10, 2023	SELL	$3.23 - $4.95 $2.08 Million - $3.19 Million	-643,616 Reduced 49.94%	645,181 $2.19 Million
Q1 2023 May 11, 2023	BUY	$2.68 - $4.79 $3.31 Million - $5.92 Million	1,235,054 Added 2298.07%	1,288,797 $6.17 Million
Q4 2022 Feb 09, 2023	BUY	$1.22 - $2.85 $63,980 - $149,462	52,443 Added 4034.08%	53,743 $153,000
Q3 2022 Nov 10, 2022	SELL	$0.59 - $1.44 $18,329 - $44,736	-31,067 Reduced 95.98%	1,300 $2,000
Q2 2022 Aug 10, 2022	BUY	$0.51 - $1.17 $9,290 - $21,313	18,217 Added 128.74%	32,367 $19,000
Q1 2022 May 12, 2022	SELL	$0.65 - $1.18 $14,467 - $26,264	-22,258 Reduced 61.13%	14,150 $15,000
Q4 2021 Feb 10, 2022	BUY	$0.86 - $1.7 $8,505 - $16,813	9,890 Added 37.3%	36,408 $40,000
Q3 2021 Nov 10, 2021	BUY	$1.27 - $8.17 $33,677 - $216,652	26,518 New	26,518 $35,000

Others Institutions Holding ARDX

# of Institutions

218

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $806M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account